Autolus Therapeutics plc

NASDAQ: AUTL
$3.73
-$0.31 (-7.7%)
Closing Price on November 8, 2024

AUTL Stock Chart and Intraday Price

AUTL Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address FOREST HOUSE, 58 WOOD LANE, WHITE CITY, LONDON, GB
Fiscal Year End September
Latest Quarter 9/30/2023
Market Cap 1,447.37M USD
Shares Outstanding 232,322,000
Autolus Therapeutics plc is a London-based biopharmaceutical company focused on pioneering T cell therapies for cancer treatment. It's known for its innovative approach in developing therapies that target specific types of cancer cells, with its leading program, obecabtagene autoleucel, showing promise in adult and pediatric acute lymphoblastic leukemia (ALL). Additionally, Autolus is exploring treatments for peripheral T-cell lymphoma and neuroblastoma, among others, through its diverse pipeline of investigational therapies. Founded in 2014, the company is at the forefront of utilizing T cell engineering to combat cancer.

AUTL Articles

Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Vir Biotechnology.
Monday’s top analyst upgrades and downgrades included Chipotle Mexican Grill, CRISPR, Hess Midstream, iMedia Brands, Kinder Morgan, Wendy’s and more.